Bayer Completes Perfuse Therapeutics Acquisition for PER-001 | Lucid Diligence Brief
Bayer has closed its acquisition of Perfuse Therapeutics, securing full rights…
Merck and Protillion Biosciences Collaboration Examined | Lucid Diligence Brief
Merck and Protillion partner on AI protein design. Assess milestones, platform…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Intravacc and SynphaBase Conjugate Vaccine Partnership | Lucid Diligence Brief
Can Intravacc and SynphaBase create a streamlined synthetic glycan-to-GMP…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing Agreement with Eli Lilly
Lucid Diligence Brief: AlzeCure Pharma Collaboration and Out-Licensing…
Nurix Roche Bexobrutideg Deal | Lucid Diligence Brief
Roche’s collaboration with Nurix turns bexobrutideg into a multi-indication BTK…
GNI Group Acquires Ayumi Pharmaceutical | Lucid Diligence Brief
GNI Group’s Ayumi acquisition tests Japan commercial scale, Calonal durability,…
Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
IDEAYA and Roche Collaboration | Lucid Diligence Brief
IDEAYA and Roche Test IDE892 plus RG6505 in MTAP-Deleted RAS-Mutant PDAC…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…